Skip to main content
. 2018 May 7;9:864. doi: 10.3389/fimmu.2018.00864

Table 4.

Univariate analysis of clinical features in successful and adverse pregnancy outcome (APO) pregnancies.

Clinical/serological features APO (n = 50) (17.7%) Successful pregnancies (n = 233) (82.3%) p-Value OR (CI 95%)
Age at the onset ≥35 years (n = 107) 20/50 (40) 87/233 (37.3) NS _
Formal diagnosis of antiphospholipid syndrome (APS) (n = 190) 38/50 (76) 152/233 (65.2) NS
Organ-specific autoimmune diseasea (n = 38) 12/50 (24) 26/233 (11.2) 0.016e 2.51 (1.09–5.75)
Previous thrombosis (n = 66) 16/50 (32) 50/233 (21.5) NS
Previous pregnancy morbidity (n = 151) 27/50 (54) 124/233 (53.2) NS
Previous premature birth (n = 32) 10/50 (20) 22/233 (9.4) 0.032f 2.39 (0.99–5.82)
Previous ≥3 spontaneous abortion (n = 29) 4/50 (8) 25/233 (10.7) NS
Prior pregnancy morbidity and thrombosis (n = 27) 5/50 (10) 22/233 (9.4) NS
Other APS-related manifestationsb (n = 48) 16/50 (32) 32/233 (13.7) 0.002f 2.95 (1.38–6.29)
Acquired risk factors for thrombosisc (n = 90) 21/50 (42) 69/233 (29.6) NS
Inherited thrombophilia (data available for 237 pregnancies)d (n = 23) 5/40 (12.5) 18/197 (9.1) NS

aAssociated autoimmune organ disease, thyroiditis, autoimmune hepatitis, primary biliary cirrhosis, psoriasis, celiac disease.

bOther APS-related manifestations, thrombocytopenia, epilepsy, headache, livedo reticularis, heart valve lesions, and hemolytic anemia.

cAcquired risk factors for thrombosis, hypertension, BMI >30 kg/m2, and smoke.

dInherited thrombophilia, factor II and factor V mutation, protein C and S and antithrombin III deficiency.

NS, not statistically significant.

eSignificant at multivariate analysis, p = 0.012 (OR 3.29, CI 95% 1.29–8.38).

fNot significant at multivariate analysis.